CY1121062T1 - Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer - Google Patents

Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer

Info

Publication number
CY1121062T1
CY1121062T1 CY181101390T CY181101390T CY1121062T1 CY 1121062 T1 CY1121062 T1 CY 1121062T1 CY 181101390 T CY181101390 T CY 181101390T CY 181101390 T CY181101390 T CY 181101390T CY 1121062 T1 CY1121062 T1 CY 1121062T1
Authority
CY
Cyprus
Prior art keywords
treatment
pharmaceutical compositions
alzheimer disease
tetrafluoropropoxy
benzylamine
Prior art date
Application number
CY181101390T
Other languages
English (en)
Inventor
Ellen Schmidt
Johan Areberg
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49118521&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CY1121062T1 publication Critical patent/CY1121062T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Η παρούσα εφεύρεση περιγράφει μεθόδους για την αντιμετώπιση της άνοιας που περιλαμβάνουν τη χορήγηση μιας αποτελεσματικής ημερήσιας δόσης Ν-(2-(6-φθορο-1Η-ινδολ-3-υλ)αιθυλ-(2,2,3,3-τετραφθοροπροποξυ)βενζυλαμίνης για τη βελτίωση ή την αύξηση της επίδρασης ενός αναστολέα ακετυλοχολινεστεράσης.
CY181101390T 2012-09-09 2018-12-21 Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer CY1121062T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698664P 2012-09-09 2012-09-09
US201361782084P 2013-03-14 2013-03-14
PCT/EP2013/068516 WO2014037532A1 (en) 2012-09-09 2013-09-06 Methods of treating alzheimer's disease and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CY1121062T1 true CY1121062T1 (el) 2019-12-11

Family

ID=49118521

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101390T CY1121062T1 (el) 2012-09-09 2018-12-21 Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer

Country Status (33)

Country Link
US (4) US9375418B2 (el)
EP (1) EP2892563B1 (el)
JP (2) JP6693744B2 (el)
KR (2) KR102342127B1 (el)
CN (1) CN104619344A (el)
AP (1) AP2015008306A0 (el)
AU (1) AU2013311573B2 (el)
BR (1) BR112015005117B1 (el)
CA (1) CA2883751C (el)
CL (1) CL2015000578A1 (el)
CY (1) CY1121062T1 (el)
DK (1) DK2892563T3 (el)
EA (1) EA030448B1 (el)
ES (1) ES2703630T3 (el)
GE (1) GEP201706776B (el)
HK (1) HK1212217A1 (el)
HR (1) HRP20182069T1 (el)
IL (1) IL237369B (el)
JO (1) JO3459B1 (el)
LT (1) LT2892563T (el)
MX (1) MX368305B (el)
MY (1) MY182539A (el)
NI (1) NI201500031A (el)
NZ (1) NZ630589A (el)
PL (1) PL2892563T3 (el)
PT (1) PT2892563T (el)
RS (1) RS58104B1 (el)
RU (1) RU2675786C2 (el)
SG (1) SG11201501774QA (el)
SI (1) SI2892563T1 (el)
TN (1) TN2015000076A1 (el)
TW (1) TWI632909B (el)
WO (1) WO2014037532A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2009074607A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
SG11201507382QA (en) 2013-03-14 2015-10-29 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
JO3639B1 (ar) 2014-07-04 2020-08-27 H Lundbeck As صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد
JP2017526716A (ja) 2014-09-12 2017-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃのスピロ環状阻害剤
US10150766B2 (en) 2014-09-12 2018-12-11 Janssen Pharmaceutica Nv P2X7 modulators
CN105175307A (zh) * 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途
CN107847499A (zh) * 2015-05-07 2018-03-27 阿速万科学有限责任公司 治疗神经退行性疾病的方法
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
BR112017026928B1 (pt) * 2016-04-26 2023-04-11 H. Lundbeck A/S Uso de idalopirdina em combinação com um inibidor de acetilcolinesterase
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
PT3484467T (pt) 2016-05-18 2020-06-16 Suven Life Sciences Ltd Combinação de antagonistas puros do recetor 5-ht6 com inibidores de acetilcolinesterase
CN106309436A (zh) * 2016-07-25 2017-01-11 宁波大学 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途
CN107118146B (zh) * 2017-04-13 2019-09-03 宁波大学 一种6-溴色胺衍生物及其制备方法和用途
KR20200007795A (ko) * 2017-05-24 2020-01-22 하. 룬드벡 아크티에셀스카브 Apoe4 대립형질을 보유하는 환자 하위집단에서 알츠하이머병의 치료에 사용하기 위한 5-ht6 수용체 길항제 및 아세틸콜린에스테라제 억제제의 조합
MX2021003661A (es) 2018-09-28 2021-08-19 Janssen Pharmaceutica Nv Moduladores de la monoacilglicerol lipasa.
TW202028198A (zh) 2018-09-28 2020-08-01 比利時商健生藥品公司 單醯基丙三醇脂酶調節劑
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv MGL PET RADIOLABE LIGANDS
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3597149A (en) 1969-04-29 1971-08-03 Showa Denko Kk Inhibition of gas-fume fading of dyed cellulose acetate material
FR2181559A1 (en) 1972-04-28 1973-12-07 Aec Chimie Organique Bio N-Phenylalkyl-N-3-indolylalkyl-alkylamines - with sedative, neuroleptic, analgesic, hypotensive, antiserotonin, adrenolytic activity
JPS5764632A (en) 1980-10-09 1982-04-19 Mitsui Toatsu Chem Inc Novel 2-arylethyl ether derivative and thioether derivative, their production and insecticide and acaricide
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5202336A (en) 1986-09-24 1993-04-13 Bayer Aktiengesellschaft Antiflammatory quinolin methoxy phenylsulphonamides
SE9103745D0 (sv) 1991-12-18 1991-12-18 Wikstroem Haakan Aryl-triflates and related compounds
DE69411143T2 (de) 1993-09-01 1998-10-22 Allelix Biopharma Tryptamin analoge mit 5-ht1d selektivität
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
DE69836559T2 (de) 1997-09-29 2007-09-13 Aventis Pharmaceuticals Inc. Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
PT1149078E (pt) 1998-12-11 2006-07-31 Univ Virginia Commonwealth Ligandos receptores de 5-ht6 selectivos
HUP0202932A3 (en) 1999-01-13 2003-07-28 Millennium Pharm Inc Heterocyclic compounds and pharmaceutical compositions can be used as chemokine receptor modulators
US6750348B1 (en) 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
ES2292758T3 (es) 2001-03-29 2008-03-16 Eli Lilly And Company N-(2-ariletil) bencilaminas como antagonistas del receptor 5-ht6.
RU2252936C2 (ru) 2002-12-05 2005-05-27 Институт физиологически активных веществ РАН S-замещенные n-1-[(гетеро)арил]алкил-n`-[(гетеро)арил]алкилизотиомочевины, способ их получения, фармацевтическая композиция, способ изучения глутаматэргической системы, способы лечения (варианты)
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
US20100120747A1 (en) 2006-06-23 2010-05-13 Laboratorios Del Dr. Esteve, S.A. Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity
AR061637A1 (es) 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
RU2012106605A (ru) * 2009-07-23 2013-08-27 ШАЙЕ ЭлЭлСи Аминокислотные и пептидные пролекарства галантамина и их применение
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
AP2015008306A0 (en) 2015-03-31
JP2015528471A (ja) 2015-09-28
BR112015005117A2 (pt) 2017-07-04
RU2675786C2 (ru) 2018-12-25
EA201590353A1 (ru) 2016-03-31
RU2015107877A (ru) 2016-10-27
US9687473B2 (en) 2017-06-27
LT2892563T (lt) 2019-01-10
US9789085B2 (en) 2017-10-17
HRP20182069T1 (hr) 2019-02-08
US20160354343A1 (en) 2016-12-08
KR20150065680A (ko) 2015-06-15
KR102342127B1 (ko) 2021-12-21
BR112015005117B1 (pt) 2022-06-21
ES2703630T3 (es) 2019-03-11
TWI632909B (zh) 2018-08-21
JO3459B1 (ar) 2020-07-05
MY182539A (en) 2021-01-25
US10660878B2 (en) 2020-05-26
US20140073681A1 (en) 2014-03-13
NI201500031A (es) 2016-02-15
CA2883751A1 (en) 2014-03-13
SI2892563T1 (sl) 2019-02-28
US9375418B2 (en) 2016-06-28
AU2013311573A1 (en) 2015-03-12
EP2892563B1 (en) 2018-11-14
JP2019059760A (ja) 2019-04-18
NZ630589A (en) 2015-12-24
US20160256437A1 (en) 2016-09-08
DK2892563T3 (en) 2019-01-21
TN2015000076A1 (en) 2016-06-29
SG11201501774QA (en) 2015-05-28
TW201414474A (zh) 2014-04-16
AU2013311573A8 (en) 2015-03-19
MX368305B (es) 2019-09-27
MX2015002879A (es) 2015-07-06
GEP201706776B (en) 2017-11-27
IL237369B (en) 2018-11-29
CN104619344A (zh) 2015-05-13
PL2892563T3 (pl) 2019-04-30
KR20200137028A (ko) 2020-12-08
IL237369A0 (en) 2015-04-30
AU2013311573B2 (en) 2017-10-12
JP6693744B2 (ja) 2020-05-13
RS58104B1 (sr) 2019-02-28
CL2015000578A1 (es) 2015-05-15
PT2892563T (pt) 2019-01-10
EA030448B1 (ru) 2018-08-31
CA2883751C (en) 2020-11-24
HK1212217A1 (en) 2016-06-10
EP2892563A1 (en) 2015-07-15
US20180071254A1 (en) 2018-03-15
WO2014037532A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201790817A1 (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1 для лечения болезни альцгеймера
EA201892219A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
PH12019501896A1 (en) Therapeutic dendrimers
PH12015502365B1 (en) Bace1 inhibitors
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
EA202090414A1 (ru) Соединения и их применение
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201692300A1 (ru) Производные карбоксамида
EA201790315A1 (ru) Модуляторы x-рецепторов печени
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
EA201590074A1 (ru) Производное бензодиоксола, способ его получения и его применение
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
PH12017501668A1 (en) Bace1 inhibitors
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний